Business ❯ Finance ❯ Investments ❯ Stocks

Pharmaceutical Stocks

Biogen to Buy Apellis for $5.6 Billion in Cash, Adding Syfovre and Empaveli

Biogen aims to use Apellis’ marketed complement drugs to speed its pivot into immunology and nephrology.

Summit Therapeutics Shares Rally as Ivonescimab Trials Near Q2 Readout

Analysts Reinforce Eli Lilly’s Bull Case on Strong 2026 Guide, GLP-1 Momentum

ImmunityBio Rallies as Anktiva Sales Surge 700% and Registrational Trial Passes 85% Enrollment

Bristol Myers Enters 2026 With Eliquis Medicaid Pact, Opdivo Qvantig Rollout, and Divergent Analyst Views

Eli Lilly Briefly Hits $1 Trillion as GLP-1 Boom Spurs Fresh Analyst Targets

Crinetics Wins FDA Approval for Oral Acromegaly Drug Palsonify as JMP Lifts Price Target